Evidence map›Paper›PMID 36090473›Full record

ArticleMolecular therapy oncolytics2022

PI3K-activated MSC proteomes inhibit mammary tumors via Hsp90ab1 and Myh9.

Xun Sun, Kexin Li, Uma K Aryal, Bai-Yan Li, Hiroki Yokota

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy oncolytics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Xun SunDepartment of Pharmacology, School of Pharmacy, Harbin Medical University, Harbin 150081, China.
Kexin LiDepartment of Pharmacology, School of Pharmacy, Harbin Medical University, Harbin 150081, China.
Uma K AryalDepartment of Comparative Pathobiology, Purdue University, West Lafayette, IN 47907, USA.
Bai-Yan LiDepartment of Pharmacology, School of Pharmacy, Harbin Medical University, Harbin 150081, China.
Hiroki YokotaDepartment of Pharmacology, School of Pharmacy, Harbin Medical University, Harbin 150081, China.
University of Indianapolis · USHarbin Medical University · CNIndiana University Health · USPurdue University West Lafayette · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the advance in medications in the past decade, aggressive breast cancer such as triple-negative breast cancer is difficult to treat. Here, we examined a counter-intuitive approach to converting human bone marrow-derived mesenchymal stem cells (MSCs) into induced tumor-suppressing cells by administering YS49, a PI3K/Akt activator. Notably, PI3K-activated MSCs generated tumor-suppressive proteomes, while PI3K-inactivated MSCs tumor-promotive proteomes. In a mouse model, the daily administration of YS49-treated MSC-derived CM decreased the progression of primary mammary tumors as well as the colonization of tumor cells in the lung. In the

Indexed as

bone metastasisbreast cancerHsp90ab1MSCMyh9PI3K/Akt

Identifiers

PMID36090473
PMCPMC9420348
OpenAlexW4289947795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.